How much does semaglutide cut alcohol craving and drinking?
The reduction is substantial and consistent across different types of studies. In a randomized controlled trial (the gold standard for medical evidence) published in 2025, 48 adults with alcohol use disorder who took low-dose semaglutide for 9 weeks experienced a 39% greater reduction in weekly alcohol craving compared to those on placebo [2]. The same trial found that semaglutide reduced the amount of alcohol consumed per drinking day by about 41% and cut the peak breath alcohol concentration during a lab drinking task by 46% [2]. These are not small effects—they translate to noticeably fewer heavy drinking days and less intoxication.
A much larger observational study of over 227,000 people with alcohol use disorder in Sweden found that those who used semaglutide had a 36% lower risk of being hospitalized for alcohol-related problems compared to periods when they were not using the drug [1]. This is a real-world measure of serious harm reduction, not just self-reported drinking. The same study found that semaglutide was more effective than officially approved medications for alcohol use disorder, which only reduced hospitalization risk by about 2% [1].
A meta-analysis combining results from 3 randomized trials and 6 observational studies (covering over 2.7 million people) confirmed that semaglutide and similar drugs reduced alcohol-related events by about 36% in observational studies, though the smaller randomized trials showed a non-significant trend toward reduced consumption [3]. The authors noted that semaglutide appeared more potent than other GLP-1 drugs for reducing craving [3].
Does semaglutide also help with food addiction or binge eating?
The evidence is more limited but points in the same direction. A case report of a woman with cocaine use disorder and recurrent binge-eating episodes found that after starting semaglutide, her binge-eating behaviors remitted completely, with scores on an eating disorder inventory returning to normal [6]. This is just one person, so it's not proof, but it aligns with how semaglutide works—it activates the same brain pathways that control appetite for both food and alcohol.
The large weight-loss trial that established semaglutide's effectiveness for obesity showed that participants lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo [5]. While this trial didn't measure food addiction specifically, such dramatic weight loss implies a major reduction in overall food intake and likely in compulsive eating. A social media analysis of over 68,000 posts about semaglutide found that among alcohol-related posts, 71% mentioned craving reduction or decreased desire to drink, suggesting people experience similar effects on food and alcohol urges [4].
However, no large randomized trial has yet tested semaglutide specifically for food addiction or binge-eating disorder. The strongest evidence for food-related effects comes from the weight-loss trials and case reports, not from dedicated studies of addictive eating.
What are the caveats and limitations?
The evidence is promising but not yet definitive. The only randomized controlled trial on alcohol use disorder used a low dose of semaglutide (up to 1.0 mg weekly) over just 9 weeks, which is a short treatment period [2]. The larger observational study, while impressive in size, cannot prove cause and effect—people who choose to take semaglutide may differ in other ways that affect their drinking [1]. The meta-analysis noted that the randomized trials showed non-significant effects on alcohol consumption and craving, meaning the results could have occurred by chance, though the observational data was highly significant [3].
Side effects are common. In the weight-loss trial, 4.5% of people stopped semaglutide due to gastrointestinal issues like nausea and diarrhea, compared to 0.8% on placebo [5]. These side effects are usually mild to moderate and temporary, but they can be a barrier for some people.
The studies here mostly involved people with obesity or type 2 diabetes who also had alcohol use disorder. It's not yet clear whether semaglutide would work as well for people of normal weight who drink heavily, or for those without metabolic conditions. Also, the effects on food addiction specifically have not been tested in large trials—most of the evidence comes from weight loss studies and case reports, not from studies of addictive eating patterns.
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2021 to 2025, 4 from 2024 or later, 4 in Q1 journals, collectively cited 4,190 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 44 papers retrieved from a database of over 500 million.
Sources used in this answer
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
In a nationwide Swedish cohort of 227,866 people with alcohol use disorder, semaglutide use was associated with a 36% lower risk of hospitalization for alcohol-related problems compared to periods of non-use, and this effect was stronger than that of approved AUD medications [1].
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
In a 9-week randomized controlled trial of 48 adults with alcohol use disorder, low-dose semaglutide reduced weekly alcohol craving by 39% and drinks per drinking day by 41% compared to placebo, with medium-to-large effect sizes [2].
The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis
A meta-analysis of 3 randomized trials and 6 observational studies (over 2.7 million participants) found that observational studies showed a 36% reduction in alcohol-related events with GLP-1 drugs, but randomized trials showed non-significant reductions in consumption and craving [3].
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
In a remote study of 153 people with obesity, those taking semaglutide or tirzepatide reported significantly lower alcohol intake, fewer drinks per drinking episode, and lower binge drinking odds compared to before starting the medication and compared to a control group [4].
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In a large randomized trial of 1,961 adults with obesity, once-weekly semaglutide (2.4 mg) led to an average 14.9% weight loss over 68 weeks, compared to 2.4% with placebo, with 86.4% of participants losing at least 5% of their body weight [6].
Semaglutide for Craving Reduction in a Cocaine Dependent Patient: A Case Report
In a case report of a woman with cocaine use disorder and binge-eating, semaglutide reduced cocaine craving scores by over 75% and completely eliminated binge-eating episodes over three months [7].